Results 31 to 40 of about 3,831 (231)

National Cohort of Compassionate Use of Meropenem–Vaborbactam: No Benefit over Meropenem for Pseudomonas aeruginosa

Antibiotics
Background: Meropenem–vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an ...
Aurélien Dinh, Alexandre Bleibtreu, Clara Duran, Frédérique Bouchand, Alexie Bosch, Jullien Crozon-Clauzel, Mariam Roncato-Saberan, Morgan Matt, André Boibieux, Annlyse Fanton, Heidi Wille, Elise Fiaux, Benoît Pilmis, Marie Lacoste, Quentin Saint-Genis, Caroline Thumerelle, Patricia Pavese, Fanny Vuotto, Eric Senneville, Anaïs Potron, Stéphane Corvec, David Boutoille, Katy Jeannot, Laurent Dortet, on behalf of the Meropenem-Vaborbactam French Study Group   +24 more
doaj   +2 more sources

Clinical Evaluation of Meropenem-Vaborbactam Combination for the Treatment of Urinary Tract Infection: Evidence to Date

Infection and Drug Resistance, 2023
Fischer Herald,1 Rodrigo M Burgos1,2 1Department of Pharmacy Practice, College of Pharmacy, University of Illinois Chicago, Chicago, IL, USA; 2Department of Medicine, College of Medicine, University of Illinois Chicago, Chicago, IL, USACorrespondence ...
Herald F, Burgos RM
exaly   +2 more sources

Meropenem-vaborbactam: a critical positioning for the management of infections by Carbapenem-resistant Enterobacteriaceae

Expert Review of Anti-infective Therapy, 2022
The review aims to review the positioning of meropenem-vaborbactam in clinical practice, taking into consideration the characteristics of other available drugs, namely ceftazidime-avibactam, plazomicin, and colistin. The search terms ‘meropenem-vaborbactam’ or RX7009 for the years 2006 until 2021 were used.
Mouktaroudi, M., Kotsaki, A., Giamarellos-Bourboulis, E.J.   +2 more
openaire   +4 more sources

Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

International Journal of Antimicrobial Agents, 2023
Meropenem in combination with β-lactamase inhibitors (BLIs) and other drugs was tested to identify alternative treatment regimens for multidrug-resistant tuberculosis (MDR-TB).The following were performed: (1) MIC experiments; (2) static time-kill studies (STKs) with different BLIs; and (3) a hollow fibre model system of TB (HFS-TB) studies with ...
Sanjay Singh, Tawanda Gumbo, Jan‐Willem C. Alffenaar, Gunavanthi D. Boorgula, Prem Shankar, Tania A. Thomas, Keertan Dheda, Lesibana Anthony Malinga, Prithvi Raj, Santosh Aryal, Shashikant Srivastava   +10 more
openalex   +5 more sources

In Vitro Activities of Cefiderocol, Ceftazidime–Avibactam, Meropenem–Vaborbactam, Imipenem–Relebactam and Eravacycline Against Carbapenem-Resistant Klebsiella pneumoniae

Journal of Global Antimicrobial Resistance
AIM/BACKGROUND: Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a significant global threat due to the limited treatment options. In this study, in vitro activities of novel antimicrobial agents were investigated against CRKP strains ...
FATMA SENA TÜRKDOĞAN, Betigul Ongen
doaj   +2 more sources

Genomic and molecular characterisation of a KPC-producing Klebsiella pneumoniae clinical isolate resistant to meropenem-vaborbactam, imipenem-relebactam, and ceftazidime-avibactam. [PDF]

BMC Genom Data
Wan Y, Wong JLC, Sanchez-Garrido J, Low WW, Turton JF, Morecchiato F, Baccani I, Dodgson K, Rossolini GM, Woodford N, Frankel G, Jauneikaite E, Meunier D, Hopkins KL.   +13 more
europepmc   +3 more sources

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem [PDF]

Antimicrobial Agents and Chemotherapy, 2018
Vaborbactam is a novel beta-lactamase inhibitor with activity against important beta-lactamases, in particular, serine carbapenemases, and is currently approved in combination with meropenem as Vabomere for the treatment of complicated urinary tract infections, including pyelonephritis.
David C. Griffith, Mojgan Sabet, Ziad Tarazi, Olga Lomovskaya, Michael N. Dudley   +4 more
openalex   +3 more sources

In vitro activity of meropenem-vaborbactam combinations and eravacycline against carbapenem-resistant Acinetobacter baumannii [PDF]

Scientific Reports
Treatment of carbapenem-resistant Acinetobacter baumannii (CRAB) presents a growing clinical challenge. This study evaluated the in vitro efficacy of eravacycline and the potential synergistic activity of meropenem-vaborbactam in combination with either ...
Amira H. El-Ashry, Ahmed Mostafa Abdrabou, Nora El-Tantawy, Rasha Mahmoud, Rasha El-Mahdy   +4 more
doaj   +2 more sources

Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study [PDF]

Background Meropenem-vaborbactam is a recent and promising option for the treatment of KPC-producing Klebsiella pneumoniae (KPC-Kp) infections, including those resistant to ceftazidime-avibactam.Methods We conducted a retrospective analysis of ...
Mario Tumbarello, Francesca Raffaelli, Maddalena Giannella, Gennaro De Pascale, Antonio Cascio, Francesco Giuseppe De Rosa, Anna Maria Cattelan, Alessandra Oliva, Annalisa Saracino, Matteo Bassetti, Cristina Mussini, Roberto Luzzati, Alessandro Capone, Liana Signorini, Michele Bartoletti, Margherita Sambo, Loredana Sarmati, Spinello Antinori, Alessandra Mularoni, Carlo Tascini, Alberto Corona, Renato Pascale, Raffaella Rubino, Silvia Corcione, Maria Mazzitelli, Gabriele Giuliano, Antonio Lovecchio, Davide Fiore Bavaro, Marianna Meschiari, Francesca Montagnani, Massimiliano Fabbiani, Ilaria De Benedetto, Massimo Antonelli, Mario Venditti, Pierluigi Viale   +34 more
core   +8 more sources

New Antibiotics Against Multidrug-Resistant Gram-Negative Bacteria in Lung Transplantation: Clinical Evidence, Safety, and PK/PD Properties [PDF]

Transplant International
Infections caused by multidrug-resistant Gram-negative bacteria (MDR-GNB) and Pseudomonas aeruginosa are leading causes of morbidity and mortality after lung transplantation (LuTx).
Andrea Lombardi, Andrea Lombardi, Davide Mangioni, Giulia Viero, Laura Alagna, Giulia Renisi, Paola Saltini, Alessandra Bandera, Alessandra Bandera   +8 more
doaj   +2 more sources